Prosensa B.V., Consultants for Research in Imaging and Spectroscopy (CRIS), Scito, Institute of Myology, Katholieke Universiteit Leuven, Leiden University Medic

Prosensa said the BIOIMAGE-NMD consortium received about €6 million ($8.1 million) from the EU's Seventh Framework Programme (FP7) to develop imaging biomarkers for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD). The project aims to develop a simultaneous MRI/Magnetic Resonance Spectroscopic Imaging (MRSI) biomarker to monitor therapeutic efficacy in clinical trials in neuromuscular diseases. The consortium, which is expected to run for three and a half years, includes Prosensa, the academic partners, medical imaging computer software company Scito and NMR consulting firm CRIS. BIOIMAGE-NMD will conduct MRI scans in a number of exon skipping products, including Prosensa's PRO053. ...